Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 1617
IM-1617 · 1 trial · 6 indications
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
| Arm | Type | Description |
|---|---|---|
| IM-1617 Dose Escalation | EXPERIMENTAL | IM-1617 given into the vein (IV; intravenously) |
| IM-1617 Monotherapy Dose Expansion | EXPERIMENTAL | IM-1617 given into the vein (IV; intravenously) |
| Name | Type | Description |
|---|---|---|
| IM-1617 | DRUG | IM-1617 is an antibody-drug conjugate |
Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 2. Part A: Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors: * CRC, all subtypes * NSCLC: * Non-squamous cell carcinoma subtypes, suc...
Top 20 of 76 competitors
IM-1617 is an investigational small molecule being studied for the treatment of advanced cancer, including colorectal cancer, non-small cell lung cancer, breast cancer, esophageal cancer, and stomach cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA.
IM-1617 is being developed by Immunome, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IMNM. The company is conducting a Phase 1 clinical trial of IM-1617 in participants with advanced cancer.
IM-1617 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 study is currently recruiting participants to evaluate the safety and tolerability of IM-1617 in patients with advanced cancer.
IM-1617 is being studied in a Phase 1 clinical trial with the identifier NCT07578571. This trial is titled 'A Phase 1 Study of IM-1617 in Participants With Advanced Cancer' and is currently recruiting participants in the United States. The trial is expected to enroll 175 participants.
Yes, IM-1617 is also known as -1617. Both names refer to the same investigational small molecule drug being developed by Immunome, Inc. for the treatment of advanced cancers, including colorectal cancer.